AstraZeneca: Zibotentan/dapagliflozin Combination Demonstrated Significant Albuminuria Reduction in Patients With Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial
November 04, 2023
November 04, 2023
WILMINGTON, Delaware, Nov. 4 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Nov. 3, 2023:
Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone.
After 12 weeks of treatment, the Phase IIb ZENITH-CKD trial showed that the UACR difference of zibotent . . .
Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone.
After 12 weeks of treatment, the Phase IIb ZENITH-CKD trial showed that the UACR difference of zibotent . . .